Clinical Trial Update: Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of Gallium-68 PSMA-11 PET imaging in intermediate to high-risk prostate cancer patients undergoing preprostatectomy has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Gallium-68 PSMA-11 PET (Gallium-68 PSMA-11)

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-12-10